Ownership history in Stonepine Capital Management, LLC Β· 4 quarters on record
This page tracks every 13F SEC filing in which Stonepine Capital Management, LLC reported a position in ABEONA THERAPEUTICS INC (ABEO). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π Stonepine Capital Management, LLC underperformed the S&P 500 by β24.0% annually on this ABEO position. Timing score: 0% (0/3 decisions correct). Average cost basis: $5.30. Maximum drawdown during holding period: β7.2%.
β Significantly underperformed the S&P 500 by 24.0% ann.
3 quarters analyzed
β οΈ Poor timing β buys often preceded drops, trims preceded rallies.
0 of 3 add/trim decisions correct
Best entry: $5.27 (2025 Q4) Β· Worst: $5.68 (2025 Q2)
π No drawdown exceeding 20% during the holding period β exceptionally stable.
3 adds Β· 1 trim. Bought during 2 of 2 down-price quarters. π Consistently bullish β fund kept accumulating this position.
π Stonepine Capital Management, LLC has been actively increasing its ABEO allocation β a bullish signal from insiders.
Currently 0.77% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size